AU2018293925B2 - A method of treatment - Google Patents

A method of treatment Download PDF

Info

Publication number
AU2018293925B2
AU2018293925B2 AU2018293925A AU2018293925A AU2018293925B2 AU 2018293925 B2 AU2018293925 B2 AU 2018293925B2 AU 2018293925 A AU2018293925 A AU 2018293925A AU 2018293925 A AU2018293925 A AU 2018293925A AU 2018293925 B2 AU2018293925 B2 AU 2018293925B2
Authority
AU
Australia
Prior art keywords
leu
ser
asn
phe
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018293925A
Other languages
English (en)
Other versions
AU2018293925A1 (en
Inventor
Doug A. BROOKS
John O'leary
Stavros SELEMIDIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Royal Melbourne Institute of Technology
Adelaide University
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
University of Adelaide
Royal Melbourne Institute of Technology Ltd
Monash University
Melbourne Institute of Technology
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902545A external-priority patent/AU2017902545A0/en
Application filed by University of Adelaide, Royal Melbourne Institute of Technology Ltd, Monash University, Melbourne Institute of Technology, College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin filed Critical University of Adelaide
Publication of AU2018293925A1 publication Critical patent/AU2018293925A1/en
Application granted granted Critical
Publication of AU2018293925B2 publication Critical patent/AU2018293925B2/en
Assigned to MONASH UNIVERSITY, ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN, Adelaide university reassignment MONASH UNIVERSITY Request to Amend Deed and Register Assignors: MONASH UNIVERSITY, ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY, THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN, UNIVERSITY OF SOUTH AUSTRALIA
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018293925A 2017-06-30 2018-06-29 A method of treatment Active AU2018293925B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902545A AU2017902545A0 (en) 2017-06-30 A method of treatment
AU2017902545 2017-06-30
PCT/AU2018/050667 WO2019000045A1 (en) 2017-06-30 2018-06-29 METHOD OF TREATMENT

Publications (2)

Publication Number Publication Date
AU2018293925A1 AU2018293925A1 (en) 2020-01-16
AU2018293925B2 true AU2018293925B2 (en) 2024-06-13

Family

ID=64740713

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018293925A Active AU2018293925B2 (en) 2017-06-30 2018-06-29 A method of treatment

Country Status (6)

Country Link
US (2) US11319343B2 (https=)
EP (1) EP3645030A4 (https=)
JP (1) JP2020527546A (https=)
CN (2) CN119548615A (https=)
AU (1) AU2018293925B2 (https=)
WO (1) WO2019000045A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11319343B2 (en) * 2017-06-30 2022-05-03 Royal Melbourne Institute Of Technology Method of treatment
WO2022170396A1 (en) * 2021-02-12 2022-08-18 ViraLok Therapeutics Pty Ltd Agents and methods for therapy and prophylaxis
CN114532296B (zh) * 2021-12-14 2023-12-15 首都医科大学附属北京同仁医院 NOX2基因缺陷rd1小鼠模型及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ525914A (en) * 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
JP2005500806A (ja) * 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
JP2011529967A (ja) * 2008-08-04 2011-12-15 イデラ ファーマシューティカルズ インコーポレイテッド アンチセンスオリゴヌクレオチドによるＴｏｌｌ様受容体７発現の調節
CN103153346A (zh) * 2010-06-16 2013-06-12 戴纳瓦克斯技术公司 使用tlr7和/或tlr9抑制剂的治疗方法
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
US9228184B2 (en) * 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
EP3560960A1 (en) 2013-04-22 2019-10-30 The University of Tokyo Preventive or therapeutic agent for inflammatory disease
CN104211799B (zh) * 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用
AU2014310935B2 (en) * 2013-08-21 2019-11-21 CureVac SE Combination vaccine
WO2015195947A1 (en) * 2014-06-20 2015-12-23 Yale University Compositions and methods to activate or inhibit toll-like receptor signaling
US11319343B2 (en) * 2017-06-30 2022-05-03 Royal Melbourne Institute Of Technology Method of treatment

Also Published As

Publication number Publication date
US20200216494A1 (en) 2020-07-09
US20220213143A1 (en) 2022-07-07
WO2019000045A1 (en) 2019-01-03
EP3645030A4 (en) 2021-04-21
JP2020527546A (ja) 2020-09-10
CN111417401A (zh) 2020-07-14
AU2018293925A1 (en) 2020-01-16
US11319343B2 (en) 2022-05-03
CN119548615A (zh) 2025-03-04
EP3645030A1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
To et al. Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy
US12102691B2 (en) Methods for efficient delivery of therapeutic molecules in vitro and in vivo
US20220213143A1 (en) Method of treatment
DK2760463T3 (en) REGULATION OF SODIUM CHANNELS USING PLUNC PROTEINS
WO2012090150A2 (en) New cell-penetrating peptides and uses thereof
Wang et al. Expression and regulation of proton-coupled oligopeptide transporters in colonic tissue and immune cells of mice
BRPI0620806A2 (pt) peptìdeos úteis como peptìdeos de penetração de célula
KR20220031545A (ko) 펩타이드 기반 비단백질성 카고 전달
CN101454341B (zh) 表面核仁素的多价合成配体在治疗癌症或发炎中的用途
US20130210749A1 (en) Peptides, constructs and uses therefor
JP7276895B2 (ja) 遺伝子発現抑制剤
WO2022202816A1 (ja) ペプチド及びペプチドを含む組成物
CN112351993A (zh) 修饰的免疫调节肽
ES2710748T3 (es) Compuestos para tratar el bloqueo de la remielinización en enfermedades asociadas con la expresión de la proteína de envoltura HERV-W
Wang et al. The RNA receptor RIG-I binding synthetic oligodeoxynucleotide promotes pneumonia survival
US7495071B2 (en) Antiproliferative peptides and antibodies for their detection
RU2813150C2 (ru) Выделенный рекомбинантный вирус на основе вируса гриппа для индукции специфического иммунитета к вирусу гриппа и/или профилактики заболеваний, вызванных вирусом гриппа
US20250333441A1 (en) Polypeptide inhibitors and uses thereof
WO2018190713A1 (en) Inhibitors of lysine methyltransferase for treatment of pain
Schulze Functional Analysis of Influenza A virus interactions with host surface proteins in influenza pneumonia
Chen Deciphering Host Immune Responses to SARS-CoV-2 Infection
Center 2050-084X
Sundaram Expression And Function Of Human IkappaBzeta In Lung Inflammation
WO2025217413A1 (en) Decoy icam-5 receptor proteins and treatment methods
Wu Unveiling the neglected roles of nucleoprotein NLS2 and cellular vimentin during Influenza A virus infection

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN

Free format text: FORMER NAME(S): THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN; MONASH UNIVERSITY; UNIVERSITY OF SOUTH AUSTRALIA; ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY

Owner name: ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY

Free format text: FORMER NAME(S): THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN; MONASH UNIVERSITY; UNIVERSITY OF SOUTH AUSTRALIA; ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY

Owner name: ADELAIDE UNIVERSITY

Free format text: FORMER NAME(S): THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN; MONASH UNIVERSITY; UNIVERSITY OF SOUTH AUSTRALIA; ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY

Owner name: MONASH UNIVERSITY

Free format text: FORMER NAME(S): THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN; MONASH UNIVERSITY; UNIVERSITY OF SOUTH AUSTRALIA; ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY